The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects.
The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad application in humans.
Cancer Therapeutics; The Peter MacCallum Cancer Centre; East Melbourne, Australia ; Cancer Immunology Program; The Peter MacCallum Cancer Centre; East Melbourne, Australia.
Alison C
AC
West
Ailsa J
AJ
Christiansen
Mark J
MJ
Smyth
Ricky W
RW
Johnstone